Abbott Laboratories (ABT) Sees 52-Week High

Advantage Investment Management LLC now owns 3,674 shares of the healthcare product maker's stock worth $163,000 after buying an additional 543 shares during the last quarter. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Startribune.com and their article: "Abbott Labs gets FDA approval for MRI-friendly defibrillator" published on September 26, 2017 as well as Investorplace.com's news article titled: "Abbott Laboratories (ABT) Raised to Buy from a Hold" with publication date: September 26, 2017. The percentage of shares being held by the company management was 0.2% while institutional stake was 71.2%. Finally, Advantage Investment Management LLC lifted its holdings in Abbott Laboratories by 17.3% during the 1st quarter. Chesley Taft & Associates LLC now owns 336,450 shares of the healthcare product maker's stock valued at $14,228,000 after buying an additional 1,441 shares during the last quarter. Lpl Llc owns 0.06% invested in Abbott Laboratories (NYSE:ABT) for 350,647 shares. State Street Corp now owns 80,499,469 shares of the healthcare product maker's stock worth $3,574,987,000 after buying an additional 12,806,535 shares during the last quarter.

Next Financial Group, Inc augmented its position by buying 902 shares an increase of 5.3% from 03/31/2017 to 06/30/2017. First Financial Bank Trust Division now owns 168,205 shares of the healthcare product maker's stock valued at $8,176,000 after purchasing an additional 510 shares in the last quarter.

Prentiss Smith & Co Inc decreased its stake in Abbott Labs (ABT) by 4.33% based on its latest 2017Q2 regulatory filing with the SEC.

Several hedge funds have recently made changes to their positions in the company. Zacks Investment Research downgraded Abbott Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, May 31st. Morgan Stanley maintained the shares of ABT in report on Tuesday, July 11 with "Equal-Weight" rating. BMO Capital Markets restated a "hold" rating and set a $53.00 price target on shares of Abbott Laboratories in a research report on Friday, September 1st. Wisconsin-based Legacy Ptnrs Inc has invested 1.72% in Abbott Laboratories (NYSE:ABT). Analysts have a mean recommendation of 2.40 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Afam has invested 0.83% of its portfolio in Abbott Laboratories (NYSE:ABT).

COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and republished in violation of U.S. and worldwide copyright laws. The legal version of this article can be accessed at https://www.truebluetribune.com/2017/09/27/abbott-laboratories-abt-holdings-cut-by-moody-lynn-lieberson-llc.html. Equities analysts expect that Abbott Laboratories will post $2.49 EPS for the current year. The stock has a 50 day moving average price of $44.58 and a 200 day moving average price of $41.35.

The stock of Abbott Laboratories (NYSE:ABT) has "Buy" rating given on Thursday, July 20 by Stifel Nicolaus. The healthcare product maker reported $0.62 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.60 by $0.02.

Abbott Laboratories has a beta of 0.82, offering the possibility of a higher rate of return, but also posing more risk. The business had revenue of $6.64 billion for the quarter, compared to analysts' expectations of $6.63 billion. During the same quarter previous year, the firm posted $0.55 EPS. The business's revenue was up 24.5% on a year-over-year basis. The company saw 2 million shares trade hands over the course of the day.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be paid a $0.265 dividend.

Start focusing on ordinary profitability ratio which covers margins; ABT has gross profit margin ratio of 54.20% for trailing twelve months and operating margin is calculated as 8.80%, these are a better detectors to find consistency or positive/negative trends in a firm's earnings. Also, insider Hubert L. Allen sold 4,600 shares of the company's stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $50.00, for a total transaction of $750,000.00. Novare Capital Management Llc bought 26,865 shares as the company's stock declined 3.42% while stock markets rallied. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Sr VP Jaime Contreras let go of 52,700 shares at an average price of $52.00 on Friday the 22nd. The stock was sold at an average price of $51.97, for a total transaction of $2,738,819.00. Insiders sold a total of 270,850 shares of company stock worth $13,549,998 over the last ninety days. The disclosure for this sale can be found here. The stock now has Monthly Volatility of 1.22% and Weekly Volatility of 1.31%.

Since March 31, 2017, it had 0 insider buys, and 1 sale for $26,482 activity.

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.